Drug Trial Radar · NCT02758353
The Impact of Sulphadoxine-Pyrimethamine Use At Scale on Newborn Outcomes in Nigeria
Last checked: Nov 20, 2026Latest source record: May 2, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
31,493
Actual
Start
Apr 2015
Primary completion
Nov 2015
Study completion Nov 2015
Sponsor
- Lead sponsor
- JSI Research & Training Institute, Inc.Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Bill and Melinda Gates Foundation; Federal Ministry of Health, Nigeria
- First posted
- May 2, 2016
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Health services research
- Who can join
- Female only
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to test the feasibility of the scale-up of sulphadoxine- pyrimethamine (SP) for the preventive treatment of malaria in pregnancy in three Local Government Areas (LGAs) in Sokoto State, Nigeria. The scale-up strategy tested included the introduction of community-based distribution of SP in addition to ongoing health facility distribution during antenatal care (ANC) visits. In addition, the study examined for the effect of SP use by participants during pregnancy on the head circumference of live newborns and on the odds of a baby being a stillborn. Finally, the investigators also sought to quantify the costs associated with program scale up SP to deliver at least three doses of SP per participant via a government operated distribution program.
Conditions
- Malaria
- Stillbirths
Interventions
Community distribution of SPDrug
SP delivered at both the community and facility level by trained CBHVs in three LGAs.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants that got SP coverage among all pregnant womenTime frame: Up to 7 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.